Nektar Wins $90 Million From Lilly Over Shelved Drug, Redefining Cost of Breaking Good-Faith Licensing Deals

A California federal jury handed Nektar Therapeutics a $90 million victory in its contract dispute with Eli Lilly over a failed autoimmune collaboration, but the September 2026 verdict represents only a fraction of what the struggling biotech sought and underscores a broader industry tension: when deep-pocketed pharma partners can walk away from licensing deals, and what it costs them when they do .

The jury found Lilly breached its contract to develop rezpeg, an autoimmune disease candidate, in good faith. The $90 million award plus interest follows a trial that played out as Lilly simultaneously notched regulatory wins elsewhere. The same week, the FDA approved Lilly's once-weekly insulin formulation, extending the company's dominance in diabetes care and demonstrating its capacity to execute when commercial incentives align . The damages award, while substantial in nominal terms, falls far below Nektar's expectations, according to reporting on the verdict. Details of the specific damages Nektar originally sought were not disclosed, but the gap between award and expectation signals the jury's skepticism about quantifying lost opportunity in early-stage drug development .

$90 million

the jury's assessment of Lilly's breach, a figure that must now be weighed against Nektar's legal costs, years of litigation drag, and the opportunity cost of capital tied up in a dispute rather than deployed into pipeline development.

The verdict matters beyond the bilateral dispute. It establishes precedent for enforceability of good-faith development obligations in licensing agreements, a clause often dismissed as boilerplate but now carrying a price tag. For institutional investors evaluating biotech partnerships, the case crystallizes tail risk: contracts have teeth, and pharma partners cannot simply de-prioritize licensed assets without financial consequence. For Lilly, the award is immaterial to a company generating tens of billions in annual revenue, but the public finding of breach carries reputational weight in future partnership negotiations.

When Good Faith Clauses Get Tested

The Nektar-Lilly dispute centers on rezpeg, a PEGylated IL-2 pathway agonist designed to treat autoimmune conditions. Nektar licensed the asset to Lilly under terms that required the pharma giant to develop the drug in good faith. The jury's conclusion that Lilly failed to meet that obligation suggests the company either deprioritized the program, reallocated resources, or terminated development in a manner the contract did not permit. Specific evidence presented at trial was not disclosed in available reporting, but the breach finding implies Lilly's internal decision-making fell short of contractual standards .

Good-faith clauses are ubiquitous in biotech licensing agreements, intended to prevent scenarios where a licensee acquires an asset to shelve it or deprioritize it once strategic priorities shift. Enforcement, however, is rare. Proving breach requires demonstrating not just that development slowed or stopped, but that the licensee failed to meet a reasonable standard of diligence. The Nektar verdict is therefore a datapoint for how courts will assess these disputes when they reach trial rather than settling.

For Nektar, the $90 million provides liquidity but not vindication on the scale the company likely projected. Biotech litigation of this type often seeks damages commensurate with projected royalties, milestone payments, and commercial upside from a successful drug launch. The jury's decision to award a figure substantially below those projections suggests either skepticism about rezpeg's commercial viability, discounting of speculative future cash flows, or a narrow interpretation of recoverable damages under contract law.

Lilly's Divergent Execution

Lilly's breach of the Nektar contract stands in sharp contrast to its execution on wholly owned assets. In the same news cycle as the verdict, the FDA approved Lilly's once-weekly insulin, a formulation that represents a significant advance in diabetes care and a major commercial opportunity . The juxtaposition is instructive: Lilly's development machine operates at world-class speed and scale when the asset fits core franchise strategy. Licensed assets from smaller partners compete for the same capital, headcount, and management attention, and when priorities shift, contractual obligations can become friction points rather than binding commitments.

The once-weekly insulin approval extends Lilly's stronghold in a market worth tens of billions annually. Diabetes franchises generate durable, high-margin revenue with predictable patient populations and favorable reimbursement dynamics. Autoimmune assets like rezpeg, by contrast, face more fragmented patient populations, complex regulatory pathways, and greater clinical risk. The resource allocation calculus is straightforward, and the Nektar verdict assigns a cost to that calculus when it conflicts with contractual duty.

Lilly's strategic focus on core franchises is not unique. Large pharma universally prioritizes wholly owned, late-stage assets in high-value therapeutic areas over earlier-stage licensed programs in riskier categories. The Nektar case simply makes explicit what partnership economics often obscure: licensing deals are asymmetric, and enforcement mechanisms matter.

Precedent and Implications for Partnership Risk

The $90 million award establishes a benchmark for breach damages in licensing disputes, but the figure itself is less important than the finding of liability. For biotech companies negotiating partnerships, the case strengthens the argument for enforceable milestone triggers, minimum development spending commitments, and reversion clauses that return rights to the licensor if progress stalls. For pharma licensees, the verdict adds legal risk to portfolio rationalization decisions and may drive more explicit termination clauses that allow clean exits at defined costs.

From an institutional capital perspective, the case highlights the fragility of value in partnered assets. Biotech valuations often embed significant option value from pharma partnerships, on the assumption that the partner's resources and expertise will maximize the asset's commercial potential. The Nektar dispute demonstrates that resource allocation is discretionary, and when priorities diverge, the biotech's recourse is litigation, a multi-year process that destroys value even when successful. The $90 million award, while a win on paper, cannot compensate for years of stalled development and lost competitive positioning.

The verdict also underscores the importance of partner selection. Not all pharma partners are equal in their commitment to licensed assets. Companies with therapeutic area focus, dedicated business units, and strategic rationale for the licensed asset are more likely to deliver on development commitments than those acquiring assets opportunistically or as pipeline fill. Due diligence on partnership risk should include analysis of the partner's track record on licensed asset development, not just their financial capacity or market reach.

The Plocamium View

The Nektar verdict is a Pyrrhic victory that exposes a structural flaw in biotech partnership economics: contracts are enforceable, but enforcement destroys value. The $90 million award, likely years in the making and reduced by legal costs, pales compared to the value Nektar would have captured had Lilly developed rezpeg successfully. The real message is not that good-faith clauses work, but that they are an inadequate remedy for misaligned incentives.

Our lens: the institutional capital opportunity is not in partnered biotech assets, but in companies that retain control of development and commercialization through later stages. The partnership model works when strategic alignment is genuine, therapeutic area focus overlaps, and the pharma partner has organizational commitment beyond the deal team that signed the contract. Absent those conditions, licensing deals are options sold too cheaply, with enforcement mechanisms that provide cash but not the commercial outcomes that drive equity value.

The second-order effect is on deal terms. Expect biotech companies with negotiating leverage to demand higher upfront payments, more aggressive milestone structures, and tighter reversion clauses. The Nektar precedent gives teeth to contract enforcement, but the smarter play is structuring deals that never require litigation. That means fewer partnerships, higher valuations for those that do occur, and greater selectivity on both sides about strategic fit.

The third-order play: private equity and growth equity backing biotechs that eschew traditional pharma partnerships in favor of building commercial infrastructure. The partnership tax, whether paid in milestones forgone or litigation costs incurred, creates an arbitrage opportunity for firms willing to fund clinical development and commercial scale-up without ceding control. The risk is higher, but the reward is unshared.

The Bottom Line

Nektar's $90 million verdict against Lilly establishes that good-faith development obligations are enforceable, but the award's scale relative to expectations reveals the limits of contract remedies in biotech partnerships. For institutional investors, the case is a reminder that partnered asset value is contingent not just on clinical and commercial risk, but on partner behavior, which is influenced by internal priorities that shift over time and are difficult to observe or enforce. The smarter capital allocation is toward biotech platforms that retain control, build their own capabilities, and partner selectively when strategic alignment is demonstrable, not aspirational. The Nektar case closed with a jury award, but the industry's partnership model remains structurally vulnerable to the same misaligned incentives that led to this dispute. Expect more litigation, tighter contracts, and fewer deals as both sides internalize the cost of failed collaboration.